Does Polymicrogyria Affect Life Expectancy?

Polymicrogyria’s effect on life expectancy ranges from negligible to severe, and the single biggest factor is how much of the brain is involved and what caused the malformation in the first place. Some people with a small, one-sided patch of abnormal cortex live full lives with only mild neurological symptoms, while infants with widespread bilateral involvement and an underlying genetic syndrome may face life-threatening complications in their first year. There is no single life-expectancy number for polymicrogyria because the condition is not one disease but a broad spectrum, and the outcomes across that spectrum look drastically different from one person to the next.

What Polymicrogyria Actually Is

Polymicrogyria, often shortened to PMG, is one of the most common malformations of cortical development. It is characterized by overfolding of the cerebral cortex and abnormal layering of the brain’s outer surface.¹ The brain’s surface normally has a pattern of ridges and grooves, but in PMG the ridges are too small and too numerous, and the layers of cells underneath are disorganized. This happens during fetal brain development, typically between about weeks 17 and 26 of gestation, when the outermost layers of the brain are still forming and migrating into position.

The malformation can affect a tiny patch of one hemisphere or stretch across both sides of the brain. It can sit around the Sylvian fissures (the deep grooves on the sides of the brain, the most common location) or involve the frontal, parietal, or occipital regions. This variability is the root cause of why prognosis differs so much from person to person. A child with a small unilateral area of PMG near the Sylvian fissure and a child with diffuse bilateral involvement effectively have different conditions sharing the same name.

What the Mortality Data Show

Hard data on PMG and life expectancy are surprisingly scarce. Most published studies focus on imaging findings, seizure patterns, or genetic causes rather than tracking survival over decades. One of the more informative population-based studies followed a cohort of patients diagnosed with PMG and found that seven patients in the group died, at a mean age of 19 months and a median age of just 5 months, with the range spanning from 1 month to about 8 years.² Three of those seven children had identified genetic syndromes involving mutations in PEX1, TUBA1A, and PEX2, respectively. In the other four, genetic testing could not identify a cause despite extensive workup.

These numbers need context. The deaths clustered in the most severely affected children, particularly those with recognized genetic syndromes that affect more than just the brain. Peroxisomal disorders (like those caused by PEX1 and PEX2 mutations, for instance) affect multiple organ systems and carry their own mortality risk independent of the brain malformation. The study does not suggest that one in every few PMG patients will die in infancy; it illustrates that the subset of patients with severe bilateral PMG and multi-system genetic conditions face the highest early mortality risk. Many other patients in the same cohort were alive and being followed, their outcomes shaped by milder disease.

Epilepsy as the Central Threat

If there is one complication that dominates the conversation about PMG and long-term survival, it is epilepsy. Seizures develop in a large majority of people with PMG, and for many of them the seizures prove difficult to control with medication alone. The reason ties back to the abnormal cortical layering: disorganized neurons fire in unpredictable patterns, making the malformed cortex a persistent seizure focus.

The link between PMG and epilepsy is especially striking when the malformation is caused by congenital cytomegalovirus (CMV) infection. A cohort study of infants with symptomatic congenital CMV found that the presence of PMG on brain imaging raised the odds of developing epilepsy roughly 35-fold compared to CMV-affected infants without PMG.³ That is a dramatic increase in risk and underscores why children with PMG, particularly those whose malformation stems from prenatal infection, need close epilepsy monitoring from early life.

Uncontrolled epilepsy is not merely a quality-of-life issue. Frequent, prolonged seizures can cause brain injury over time. Status epilepticus, where a seizure lasts more than five minutes or occurs in rapid succession without recovery, is a medical emergency that can be fatal. And even when individual seizures are brief, people with drug-resistant epilepsy face a small but real ongoing risk of sudden unexpected death in epilepsy (SUDEP), a phenomenon in which a person with epilepsy dies suddenly without another identifiable cause. The combination of these risks is the primary mechanism through which PMG-related epilepsy can shorten life.

When Seizures Do Not Respond to Medication

A frustrating reality of PMG-related epilepsy is that seizures frequently resist standard anticonvulsant drugs. In adults with unilateral PMG, one study found that seven out of eight patients had partial-onset seizures that were medically intractable, meaning medication could not adequately control them.⁴ That is a high rate of drug resistance even by the standards of structural epilepsy, and it helps explain why surgical evaluation often enters the picture.

Epilepsy surgery in PMG has been studied with increasing rigor. A subject-level meta-analysis examining surgical outcomes found that at 12 months or more of follow-up, roughly 70% of operated patients achieved seizure freedom.⁵ A separate systematic review confirmed a similar figure, reporting that about 65% of patients who underwent neurosurgery for PMG-related epilepsy reached seizure freedom based on standard outcome scales, and that a shorter duration of epilepsy before surgery was associated with better results.⁶

These are encouraging numbers, but they come with caveats. Surgery is only an option when the seizure focus can be localized to a region that can be safely removed or disconnected. For people with bilateral PMG, a large hemispheric procedure may be considered, but the decision-making is more complex. The meta-analysis noted that hemispheric surgery increased the odds of seizure freedom compared to more limited resections, though the difference did not reach statistical significance in the pooled data.⁵ For patients with unilateral or non-hemispheric bilateral PMG, more limited resections achieved similar seizure-freedom rates with fewer motor complications, suggesting that aggressive surgery is not always necessary to get a good outcome.

The take-home point for life expectancy is that achieving seizure control, whether by medication, surgery, or a combination, is the single most impactful thing that can be done to reduce mortality risk for someone with PMG. Each year of uncontrolled drug-resistant epilepsy adds cumulative exposure to the dangers of seizures, and early surgical evaluation when drugs fail may improve both survival and developmental trajectory.

Adults with Polymicrogyria

It is easy, when reading the pediatric literature on PMG, to come away with the impression that it is purely a childhood condition with grave outcomes. In reality, many people with PMG reach adulthood, and some live with remarkably little functional impairment. The same study of adults with unilateral PMG and epilepsy found that six out of eight patients had normal intelligence, while two had mild intellectual disability.⁴ Seven of the eight had mild one-sided weakness, but this did not prevent them from functioning independently. Their main ongoing challenge was the intractable epilepsy itself.

This pattern, where the neurological deficits are manageable but the seizures are the persistent problem, is common in milder forms of PMG. A person with focal unilateral PMG may have gone undiagnosed until they presented with seizures in adolescence or early adulthood, at which point brain imaging revealed the malformation. For these individuals, life expectancy is shaped almost entirely by how well their epilepsy can be managed. If seizures come under control, there is no inherent reason the malformation itself would shorten life.

Bilateral perisylvian PMG, one of the more recognized subtypes, tends to cause more noticeable symptoms from childhood: difficulty with tongue and jaw movements, problems with speech and swallowing, and often epilepsy.⁷ But even within this subtype, there are children who present with seizures and oromotor difficulties yet attend school, communicate (sometimes with augmentative devices), and grow into adults. The bilateral perisylvian form sits in the middle of the severity spectrum: more involved than a small unilateral patch but far less threatening than the diffuse bilateral forms seen in certain genetic syndromes.

Why the Underlying Cause Shapes Everything

PMG is not caused by a single gene or a single insult. It can result from genetic mutations, prenatal infections, disruptions to blood flow during fetal development, and sometimes no identifiable cause at all. The underlying etiology matters enormously for prognosis because it determines whether the brain malformation is an isolated problem or one piece of a larger syndrome.

On the genetic side, researchers have identified a number of genes linked to PMG. One of the best characterized is GPR56 (now also called ADGRG1), mutations in which cause a form called bilateral frontoparietal polymicrogyria. In a study of 29 patients with this specific subtype, all carried homozygous GPR56 mutations, and the clinical picture included white-matter abnormalities, cerebellar involvement, and sometimes eye problems in addition to the cortical malformation.⁸ Other genetic causes include mutations in TUBA1A (a tubulin gene involved in neuronal migration), PIK3CA (associated with overgrowth syndromes), and a growing list of other genes. When PMG is part of a multi-system genetic syndrome, the non-brain features of the syndrome, including metabolic dysfunction, organ malformations, or immune deficiency, can carry their own mortality risks that compound whatever danger the brain malformation poses.

The population-based cohort study that documented early deaths illustrates this directly: the three children with identified genetic causes had mutations in PEX1, TUBA1A, and PEX2.² PEX1 and PEX2 mutations cause peroxisome biogenesis disorders, conditions that affect the liver, kidneys, and other organs alongside the brain. For these children, PMG was one visible sign of a much broader disease process. Contrast that with someone whose PMG resulted from a focal vascular disruption during fetal development: the brain malformation is localized, no other organs are affected, and the prognosis looks entirely different.

Congenital CMV, one of the most common non-genetic causes of PMG, introduces its own set of complications: hearing loss, vision problems, and liver involvement can all accompany the brain malformation. The epilepsy risk is sharply elevated, as noted earlier, and children with CMV-related PMG often have more widespread brain damage beyond just the polymicrogyric cortex. Their long-term outlook depends on the full burden of CMV-related injury, not the PMG alone.

Complications Beyond Seizures

Epilepsy gets the most attention, but it is not the only way PMG can affect health and survival. Depending on the location and extent of the malformation, several other complications can arise:

• Feeding difficulties: Children with bilateral perisylvian PMG often have trouble coordinating the muscles of the mouth, tongue, and throat. This can lead to aspiration, where food or liquid enters the airway instead of the esophagus. Recurrent aspiration pneumonia is a serious concern in severely affected children and can be life-threatening if not managed with modified feeding techniques or, in some cases, a gastrostomy tube.
• Respiratory complications: Beyond aspiration, some children with severe PMG have reduced muscle tone in the upper airway or impaired coordination of breathing. These issues are more common in children with diffuse bilateral PMG or associated syndromes that affect muscle function broadly.
• Motor disability: Spastic weakness on one or both sides of the body is common. While this is rarely life-threatening on its own, severe motor disability limits mobility and increases the risk of secondary complications like pressure injuries, deep-vein blood clots, and infections associated with prolonged immobility.
• Intellectual disability: The degree varies enormously. As the adult study showed, people with focal unilateral PMG may have completely normal intelligence. Those with bilateral or diffuse forms are more likely to have moderate to severe intellectual disability, which affects their ability to communicate symptoms, manage medications, and participate in their own care.

Feeding and respiratory problems are particularly relevant to life expectancy in the most severe cases. In pediatric neurology more broadly, aspiration pneumonia is one of the leading causes of death in children with severe brain malformations, and PMG is no exception. Proactive management of swallowing safety, including early swallowing assessments and appropriate feeding supports, can meaningfully reduce this risk.

The Importance of Multidisciplinary Care

Because PMG can affect so many domains of function, no single specialist can manage it alone. Children and adults with PMG typically benefit from coordinated input across neurology, rehabilitation medicine, speech and language therapy, nutrition, and sometimes neurosurgery. When PMG occurs in the context of a broader genetic syndrome, geneticists, metabolic specialists, and other organ-specific physicians also become part of the team. Case studies of conditions that overlap with PMG, such as PIK3CA-related overgrowth spectrum, have emphasized the need for multidisciplinary care and ongoing neuroimaging surveillance to catch evolving complications before they become emergencies.⁹

For families navigating a new PMG diagnosis, the question “will my child have a normal lifespan?” is often the first and most urgent one asked. The honest answer is that it depends on the specific situation, and a care team that knows the extent and cause of the malformation is in the best position to give a realistic picture. Genetic testing is increasingly routine and can identify whether the PMG is part of a syndrome that carries additional risks. If it is isolated and focal, reassurance is appropriate. If it is bilateral and associated with a multi-system condition, the conversation shifts toward anticipating and managing specific complications.

Common Misconceptions

One widespread misunderstanding is that any brain malformation detected on imaging equals a devastating prognosis. PMG is sometimes found incidentally on MRI scans done for other reasons, and the person may have lived for decades with no or minimal symptoms. Discovering the malformation does not change the person’s trajectory; it simply provides an explanation for symptoms they may or may not have.

Another misconception is that PMG is always progressive, meaning the brain malformation gets worse over time. It does not. PMG is a malformation that forms during fetal development and then remains structurally stable. The brain does not continue to “misfold” after birth. What can change over time is the clinical picture: epilepsy may emerge, developmental delays may become more apparent as peers advance, and secondary complications may develop. But the underlying malformation itself is static. This distinction matters because it means interventions like epilepsy surgery or feeding support are addressing manageable complications, not fighting a degenerative process.

A third misconception, particularly common online, is that epilepsy surgery for PMG is experimental or rarely successful. The evidence suggests otherwise. With roughly two-thirds to 70% of carefully selected surgical patients achieving seizure freedom, surgery for PMG-related epilepsy has outcomes comparable to epilepsy surgery for other structural causes.⁶ The key phrase is “carefully selected”: not every person with PMG and seizures is a surgical candidate, but for those who are, the procedure is a well-established part of the epilepsy treatment toolkit, not an unproven gamble.

When the Diagnosis Comes Before Birth

Advances in fetal MRI have made it possible to detect PMG before a child is born, though the accuracy of prenatal imaging for cortical malformations has its limitations. The cortex is still maturing during the second and third trimesters, and some of the features of PMG may not become visible until later in gestation or even postnatally. A prenatal suspicion of PMG may be confirmed, refined, or occasionally ruled out on postnatal MRI.

For expectant parents, a prenatal finding of possible PMG is understandably alarming. Knowing that the spectrum is vast can be both reassuring and frustrating: reassuring because many outcomes are far better than the worst-case scenarios found in a late-night internet search, and frustrating because the prenatal imaging often cannot tell you exactly where on that spectrum a particular child will fall. The location, extent, and cause of the malformation all influence prognosis, and some of those details only become clear after birth, genetic testing, and developmental follow-up over months and years. Prenatal counseling in these situations benefits from the involvement of pediatric neurologists and geneticists who can walk families through the range of possibilities rather than offering a single grim or rosy prediction.

How Age at Seizure Onset Factors In

Among the many variables that influence long-term outcome, the age at which seizures begin carries particular weight. Children who develop seizures in infancy, especially before six months of age, tend to have more severe epilepsy, more widespread brain involvement, and worse developmental outcomes than those whose seizures start later. This is partly a marker of severity: more extensive PMG produces symptoms earlier. But it also reflects the vulnerability of the developing brain to repeated seizures during a critical period of growth and connectivity.

The surgical literature reinforces this from the treatment side. The finding that a shorter duration of epilepsy before surgery is associated with better outcomes suggests that early intervention, when feasible, can make a meaningful difference.⁶ Waiting years while trying successive medications that do not work may allow ongoing seizures to further compromise development. For children with clearly drug-resistant epilepsy and a localizable seizure focus, an earlier conversation about surgical options may serve them better than a prolonged trial-and-error approach with medications alone. Cognitive improvements after surgery were observed mainly in patients operated at a younger age, which adds a developmental argument to the survival one.